tetano
Editor, Senior Moderator
Front Immunol
. 2022 Mar 16;13:845969.
doi: 10.3389/fimmu.2022.845969. eCollection 2022.
MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
Robbert Boudewijns[SUP] 1 [/SUP], Patricia Pérez[SUP] 2 3 [/SUP], Adrián Lázaro-Frías[SUP] 2 3 [/SUP], Dominique Van Looveren[SUP] 4 [/SUP], Thomas Vercruysse[SUP] 4 [/SUP], Hendrik Jan Thibaut[SUP] 4 [/SUP], Birgit Weynand[SUP] 5 [/SUP], Lotte Coelmont[SUP] 1 [/SUP], Johan Neyts[SUP] 1 [/SUP], David Astorgano[SUP] 2 [/SUP], Dolores Montenegro[SUP] 6 [/SUP], Eugenia Puentes[SUP] 6 [/SUP], Esteban Rodríguez[SUP] 6 [/SUP], Kai Dallmeier[SUP] 1 [/SUP], Mariano Esteban[SUP] 2 [/SUP], Juan García-Arriaza[SUP] 2 3 [/SUP]
Affiliations
Abstract
To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.
Keywords: COVID-19; MVA vaccine; SARS-CoV-2; efficacy; hamsters; immunogenicity; spike.
. 2022 Mar 16;13:845969.
doi: 10.3389/fimmu.2022.845969. eCollection 2022.
MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
Robbert Boudewijns[SUP] 1 [/SUP], Patricia Pérez[SUP] 2 3 [/SUP], Adrián Lázaro-Frías[SUP] 2 3 [/SUP], Dominique Van Looveren[SUP] 4 [/SUP], Thomas Vercruysse[SUP] 4 [/SUP], Hendrik Jan Thibaut[SUP] 4 [/SUP], Birgit Weynand[SUP] 5 [/SUP], Lotte Coelmont[SUP] 1 [/SUP], Johan Neyts[SUP] 1 [/SUP], David Astorgano[SUP] 2 [/SUP], Dolores Montenegro[SUP] 6 [/SUP], Eugenia Puentes[SUP] 6 [/SUP], Esteban Rodríguez[SUP] 6 [/SUP], Kai Dallmeier[SUP] 1 [/SUP], Mariano Esteban[SUP] 2 [/SUP], Juan García-Arriaza[SUP] 2 3 [/SUP]
Affiliations
- PMID: 35371064
- PMCID: PMC8966703
- DOI: 10.3389/fimmu.2022.845969
Abstract
To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.
Keywords: COVID-19; MVA vaccine; SARS-CoV-2; efficacy; hamsters; immunogenicity; spike.